BioNTech is losing its chief strategy officer, with Ryan Richardson set to leave the company at the end of September to ...

BioNTech SE's turn toward oncology treatments has the potential to tap multi-billion-dollar markets in the future. Find out ...

CureVac N.V. (NASDAQ:CVAC) is among the 13 Best German Stocks to Invest in Now. The stock has gained by over 16% in the past month, with a major surge following the June 12 announcement that the ...

Detailed price information for America's Car-Mart (CRMT-Q) from The Globe and Mail including charting and trades.

Later in the month, on June 12, BioNTech SE (NASDAQ:BNTX) announced that it would acquire CureVac for approximately $1.25 billion in shares, which is expected to further strengthen the company’s ...

On June 12, 2025, BioNTech SE (“BioNTech”) announced its entry into a definitive purchase agreement to acquire all shares of CureVac N.V. (“CureVac”), with an implied aggregate equity ...

In October 2024, the UK High Court ruled in favour of Pfizer and BioNTech in their dispute with CureVac over patents related to COVID-19 vaccines. The court determined that two European patents ...

Shares of CureVac N.V. CVAC have skyrocketed 40.8% in a month after the company signed a definitive agreement to be acquired by BioNTech SE BNTX in an all-stock transaction last week. Per the ...

German vaccine manufacturer BioNTech has acquired its domestic competitor CureVac, taking over all of its shares in a transaction that values the company at approximately $1.25 billion. Mainz ...

BioNTech SE and CureVac N.V. announced that they have entered into a definitive purchase agreement pursuant to which BioNTech intends to acquire all of the shares of CureVac, a clinical-stage ...

BioNTech’s $1.25 billion deal for CureVac reshapes mRNA vaccine landscape. BioNTech is acquiring CureVac, a German and Boston biotech that just a few years ago sued it over patents for its COVID-19 ...

German biotechnology company BioNTech will buy CureVac, which specializes in mRNA-based therapeutics, in a deal valued at approximately $1.25 billion. With the deal, BioNTech aims to strengthen its ...